In a clinical scenario, 64Cu PET could therefore provide additional information for the clinical management of prostate cancer: The expression level of hCtr1 may correlate with the aggressiveness or prognosis of prostate cancer, and hCtr1 expression could be linked to the response of prostate cancer to cisplatin chemotherapy, as hCtr1 has recently been reported to mediate cellular uptake of cisplatin [26]. Here, SLC31A1 is linked to prostate cancer.